GIOSTAR awaits approval for Type 2 Diabetes Clinical Trial by FDA

We are proud to share the news that GIOSTAR is in the process of approval from the United States of Food and Drug Administration (FDA) to conduct type 2 diabetes clinical trials focused on the development of stem cell treatment. Lead by our Chairman and Co-Founder Dr. Anand Srivastava, a team of scientist are investigating a new approach to fight this disease.

More than 150 clinical trials listed on the National Institutes of Health (NIH) website have shown the potential benefits of stem cell transplant to treat diabetes.

You can read the full article here

 

In the meantime, in GIOSTAR Mexico, we work under the laws of our country; we are regulated by COFEPRIS (Mexican FDA) that allows to treat conditions that you can’t have treated in the USA.